The authors further developed a novel nanosatellite vaccine delivery system incorporating STING agonist and tumor antigens and demonstrated a rapid accumulation in the lymph node, improved IFN-I signaling and TIL in the tumor microenvironment 65. The gene discussed is STING1; the disease is neoplasm.